The company has appointed Albert Bourla, PhD, as its new COO.
Pfizer announced on Nov. 13, 2017 that it appointed Albert Bourla, PhD, as its new COO, effective Jan. 1, 2018.
Since early 2016, Dr. Bourla has been the group president of Pfizer’s innovative health business, and has held a range of senior global positions. He holds a PhD degree in the biotechnology of reproduction from the Veterinary School of Aristotle University.
“The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer chairman and CEO.
Source: Pfizer
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.